<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03673605</url>
  </required_header>
  <id_info>
    <org_study_id>PE/NICVD/TS/Rivo/01</org_study_id>
    <nct_id>NCT03673605</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin</brief_title>
  <official_title>Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis Among Pakistani Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmEvo Pvt Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmEvo Pvt Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title: Efficacy and safety of rivaroxiban compare with vitamin K antagonist warfarin in&#xD;
      patients with atrial fibrillation and mitral stenosis among Pakistani population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation is associated with an increase in the risk of ischemic stroke by a factor&#xD;
      of four to five and accounts for up to 15% of strokes in persons of all ages and 30% in&#xD;
      persons over the age of 80 years. The use of vitamin K antagonists is highly effective for&#xD;
      stroke prevention in patients with non-valvular atrial fibrillation and is recommended for&#xD;
      persons at increased risk. However, food and drug interactions necessitate frequent&#xD;
      coagulation monitoring and dose adjustments, requirements that make it difficult for many&#xD;
      patients to use such drugs in clinical practice.&#xD;
&#xD;
      Rivaroxaban is a direct factor Xa inhibitor that may provide more consistent and predictable&#xD;
      anticoagulation than warfarin. It has been reported to prevent venous thromboembolism more&#xD;
      effectively than enoxaparin in patients undergoing orthopedic surgery and was non-inferior to&#xD;
      enoxaparin followed by warfarin in a study involving patients with established venous&#xD;
      thrombosis. This trial was designed to compare once-daily oral rivaroxaban with dose-adjusted&#xD;
      warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular&#xD;
      atrial fibrillation who were at moderate-to-high risk for stroke&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patients Enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">December 30, 2016</start_date>
  <completion_date type="Actual">December 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging</measure>
    <time_frame>12 months</time_frame>
    <description>Intracranial bleeding: symptomatic hemorrhage confirmed by CT or MRI or asymptomatic hemorrhage on follow-up GRE or SWI imaging at 1 month Recurrent ischemic lesion: symptomatic ischemic stroke confirmed by relevant neuroimagings or asymptomatic recurrent ischemic lesion on follow-up or FLAIR imaging at 12 month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects/complications of Rivaroxiban as compared to Warfarin in patients with Mitral Stenosis and AF.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Mitral Valve Stenosis</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 15 mg</intervention_name>
    <description>Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin in stroke prevention in patients with Mitral Stenosis and AF.</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both gender&#xD;
&#xD;
          -  Age from 18 years up to 55 years&#xD;
&#xD;
          -  Rheumatic MS (Mild moderate severe) Hemodynamic ally stable patients&#xD;
&#xD;
          -  Associated AF or flutter documented on ECG&#xD;
&#xD;
          -  Post PTMC or M com&#xD;
&#xD;
          -  Not previously enrolled in any trial or study on NOACS&#xD;
&#xD;
          -  Willing to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rheumatic valve other than MS&#xD;
&#xD;
          -  Prosthetic Mitral Valve Surgery&#xD;
&#xD;
          -  Previous TIA or stroke&#xD;
&#xD;
          -  Plan for valve replacement within six months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of bleeding complication&#xD;
&#xD;
          -  High Risk of bleeding complication&#xD;
&#xD;
          -  Allergic to study drug&#xD;
&#xD;
          -  Anemia (HB less than 10 g/dl)&#xD;
&#xD;
          -  Raised SGPT &gt; 2xUNL&#xD;
&#xD;
          -  Creatinine clearance &lt;30ml/min&#xD;
&#xD;
          -  Not willing to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Cardiovascular</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Mitral Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

